| HIV integrase inhibitors | Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA. (12 Dec 1998) |
|---|---|
| HIV long-terminal repeat | Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription. (12 Dec 1998) |
| HIV protease | <enzyme> Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. Registry number: EC 3.4.23.- (12 Dec 1998) |
| HIV protease inhibitors | Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly. (12 Dec 1998) |
| HIV seronegativity | Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. (12 Dec 1998) |
| HIV seropositivity | Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/lav). (12 Dec 1998) |
| HIV seroprevalence | Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV seropositivity). (12 Dec 1998) |
| HIV test | <investigation> A test which is performed on a standard venipuncture blood specimen which detects the presence of antibodies to HIV (virus). This test may not be positive for 3 to 6 months after infection with HIV. (27 Sep 1997) |
| HIV wasting syndrome | <syndrome> Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhoea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofibre degeneration. A variety of aetiologies, which vary among patients, contributes to this syndrome. (12 Dec 1998) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |